Introduction {#s1}
============

Asthma is a heterogeneous disease that affects more than 315 million people worldwide, with various factors influencing its severity and control \[[@C1]--[@C3]\]. Approximately 10% of patients have severe, uncontrolled asthma, which is associated with substantial disease burden, diminished health-related quality of life and increased healthcare resource utilisation \[[@C4]--[@C6]\]. Patients with severe asthma require high-dosage inhaled corticosteroid (ICS) plus long-acting β~2~-agonist (LABA) combination therapy and often additional controller medications, including oral corticosteroids (OCSs) for disease control \[[@C7]\]. However, even with these therapies, many patients with severe asthma continue to have uncontrolled symptoms and poor asthma control, emphasising the need for new treatment options \[[@C5]\].

Eosinophilic inflammation of the airways is an important feature of asthma that affects ∼50% of patients, and is associated with increased disease severity, exacerbation frequency and symptom burden, together with decreased lung function \[[@C8]--[@C10]\]. Therapeutic approaches to reduce eosinophilic inflammation that target the interleukin (IL)-5 receptor α and anti-IL-5 monoclonal antibodies have demonstrated clinical efficacy for patients with severe asthma and evidence of eosinophilic inflammation, based on elevated blood eosinophil counts \[[@C11]--[@C15]\]. Elevated blood eosinophil counts are practical to measure and demonstrate significant associations with eosinophilic airway inflammation, but the measure is indirect and lacks specificity, especially at low eosinophil counts \[[@C16]--[@C18]\]. Additional clinical features beyond blood eosinophilia need to be identified to aid in the selection of patients who might benefit from these novel treatments.

Benralizumab is a humanised, afucosylated, monoclonal antibody that targets the IL-5 receptor α \[[@C19]\]. In contrast to anti-IL-5 monoclonal antibodies, benralizumab exerts its effect by inducing the direct, rapid and nearly complete depletion of blood eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity, an apoptotic process of eosinophil elimination involving natural killer cells \[[@C19], [@C20]\]. Airway eosinophils (tissue and sputum) are also extensively depleted \[[@C21], [@C22]\]. Two Phase III trials, SIROCCO ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT01928771) and CALIMA ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT01914757), demonstrated that benralizumab in combination with high-dosage ICS/LABA, with or without additional controllers, significantly reduced asthma exacerbations and improved lung function and disease control for patients with severe, uncontrolled asthma and blood eosinophil counts ≥300 cells·µL^−1^ *versus* placebo \[[@C11], [@C12]\]. A third Phase III trial, ZONDA ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier NCT02075255), demonstrated that for OCS-dependent patients, benralizumab significantly reduced the use of maintenance prednisone while maintaining asthma control \[[@C23]\]. Benralizumab 30 mg subcutaneous formulation administered every 8 weeks (Q8W, first three doses every 4 weeks (Q4W)) has subsequently been approved in several markets as add-on maintenance treatment for patients with severe, uncontrolled eosinophilic asthma \[[@C24], [@C25]\].

Statistical analyses of the Phase III studies identified several baseline clinical factors associated with enhanced efficacy to benralizumab, regardless of blood eosinophil counts, including OCS use, history of nasal polyposis, lung function based on pre-bronchodilator forced vital capacity (FVC), exacerbation frequency and age at asthma diagnosis \[[@C26]\]. The current study evaluates these factors in the pooled SIROCCO and CALIMA patient population, including subsets of those with blood eosinophil counts \<300 and ≥300 cells·µL^−1^.

Methods {#s2}
=======

Study design and participants {#s2a}
-----------------------------

SIROCCO and CALIMA were randomised, double-blind, parallel-group, placebo-controlled, global Phase III studies \[[@C11], [@C12]\]. The study design comprised an enrolment visit (week −4), a 4-week screening/run-in phase, randomisation (week 0), a treatment period from weeks 0 to 48 (SIROCCO) or 56 (CALIMA) and a final follow-up visit 8 (SIROCCO) or 4 (CALIMA) weeks following the end-of-treatment (EOT) period.

Enrolment criteria for the studies have been previously reported \[[@C11], [@C12]\]. The studies included male and female patients aged 12--75 years with weight ≥40 kg and physician-diagnosed asthma that required treatment with medium/high-dosage ICS/LABA for ≥12 months before enrolment. Studies were conducted in accordance with the Declaration of Helsinki, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice guidelines and the ethics committee at each participating site.

For both studies, patients were randomised 1:1:1 to receive either *s.c.* benralizumab 30 mg Q4W, benralizumab 30 mg Q4W for the first three doses followed by Q8W for the remainder of the treatment period or placebo (Q4W). For SIROCCO and CALIMA, patients with baseline blood eosinophil counts ≥300 and \<300 cells·µL^−1^ were stratified at a ratio of 2:1, respectively.

Outcomes {#s2b}
--------

The primary efficacy end-point for SIROCCO and CALIMA was the annual asthma exacerbation rate (AER). For both studies, the primary analysis set included patients receiving high-dosage ICS/LABA with baseline blood eosinophil counts ≥300 cells·µL^−1^. Secondary end-points for the primary analysis population evaluated in this current study were change from baseline at EOT for pre-bronchodilator forced expiratory volume in 1 s (FEV~1~), measured by spirometry, total asthma symptom score (a composite of daytime and night-time symptoms scored 0--6 points overall) and Asthma Control Questionnaire 6 (ACQ-6) score. ACQ-6 is a six-item questionnaire to assess daytime and night-time symptoms and rescue β-agonist use on a 0--6-point scale (small numbers represent better control) \[[@C27]\]. Details on efficacy measurement methods have been published previously \[[@C11], [@C12]\].

In the current study, analyses were performed for the pooled population of patients from the SIROCCO and CALIMA studies receiving high-dosage ICS/LABA. Baseline patient factors were selected for evaluation in this study based on the results of four separate statistical analyses and by considering features that are commonly associated with an eosinophilic asthma phenotype \[[@C28], [@C29]\]. Two of the approaches explored the relative importance of different response factors for the same population \[[@C26]\], a third approach compared patients from a pooled analysis of SIROCCO and CALIMA on defined efficacy improvements with benralizumab, and the fourth approach evaluated patients from ZONDA based on reduction in OCS dosage with benralizumab (more details provided in [supplementary appendix E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials), and [supplementary tables E1 and E2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)) \[[@C23]\]. These baseline factors include OCS use (yes/no); presence of nasal polyps (yes/no); low lung function based on pre-bronchodilator FVC categories of \<65% and ≥65% of predicted (categories based on a quartile analysis of baseline FVC % pred of the pooled SIROCCO and CALIMA data; see [supplementary appendix E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials) and [supplementary figure E1)](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials); exacerbations in the 12 months before enrolment categories of two and three or more; and age at diagnosis categories of \<18 and ≥18 years (see [supplementary appendix E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials) for rationale). Subgroups analysed within these categories were baseline blood eosinophil counts (≥300 and \<300 cells·μL^−1^). For this study, end-points evaluated were AER, and change from baseline to EOT in pre-bronchodilator FEV~1~, total asthma symptom score and ACQ-6 score.

Statistical analyses of end-points {#s2c}
----------------------------------

We performed analyses based on the full analysis set according to the intention-to-treat principle for the pooled data from the SIROCCO and CALIMA studies. This set included all randomised patients who received high-dosage ICS/LABA and any study treatment, regardless of their protocol adherence, and continued participation in the study. The similar design of the two studies allowed for the results to be pooled, which enabled us to obtain more accurate estimates of the relationships between efficacy end-points and OCS use at baseline, presence of nasal polyps and FVC % pred. Analyses were performed with SAS versions 9.2, 9.3 and 9.4 (SAS Institute, Cary, NC, USA).

We analysed exacerbation rates using a negative binomial model, with adjustments for treatment, study region (all groups), prior exacerbations and OCS use at time of randomisation where applicable for all patients and for those with blood eosinophil counts ≥300 cells·μL^−1^. The log of each patient\'s corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred. We determined the estimated AER treatment effect (*i.e.* the rate ratio of benralizumab *versus* placebo), corresponding 95% confidence interval and two-sided p-value for the rate ratio. Pre-bronchodilator FEV~1~, total asthma symptom score and ACQ-6 were analysed using a mixed-effects model for repeated measures analysis, with adjustments for treatment, study, baseline value, visit, visit×treatment and region (all groups), and, where applicable, OCS use at time of randomisation for all patients and for those with blood eosinophil counts ≥300 cells·μL^−1^. The EOT visit for each study was included in the model and used as the primary time-point.

To account for the 2:1 stratification for baseline blood eosinophil counts (≥300 and \<300 cells·μL^−1^) in analyses for all patients, we reweighted patients with baseline blood eosinophil counts \<300 cells·μL^−1^ by using the ratio of the number of patients with baseline blood eosinophil counts ≥300 cells·μL^−1^ to the number of those who had counts \<300 cells·μL^−1^. Given the smaller number of patients with blood eosinophil counts \<300 cells·μL^−1^ and the respective baseline factors evaluated, only adjustments for study code and treatment for the negative binomial model and for study code, treatment, baseline value, visit and visit×treatment for the mixed-effects model for repeated measures analysis were used within this subgroup of patients.

We calculated least squares means, treatment differences in least squares means, 95% confidence intervals and p-values. As these analyses were not part of the formal testing strategy, all p-values were nominal.

Results {#s3}
=======

Demographics and baseline clinical characteristics {#s3a}
--------------------------------------------------

The three treatment groups shared similar demographics and baseline clinical characteristics, particularly for the baseline factors evaluated in this study ([table 1](#TB1){ref-type="table"}).

###### 

Patient demographic and baseline clinical characteristics (full analysis set, pooled)^\#^

                                                            **Placebo**       **Benralizumab 30 mg Q4W**   **Benralizumab 30 mg Q8W**
  ----------------------------------------------------- -------------------- ---------------------------- ----------------------------
  **Patients**                                                  777                      756                          762
  **Age years**                                              49.2±14.6                50.4±13.2                    48.8±14.0
  **Sex**                                                                                                 
   Male                                                       287 (37)                 251 (33)                     285 (37)
   Female                                                     490 (63)                 505 (67)                     477 (63)
  **Ethnicity**                                                                                           
   White                                                      623 (80)                 593 (78)                     597 (78)
   Black or African-American                                   28 (4)                   23 (3)                       28 (4)
   Asian                                                      87 (11)                  95 (13)                      90 (12)
   Other^¶^                                                    39 (5)                   45 (6)                       47 (6)
  **BMI^+^ kg·m^−2^**                                         29.1±6.8                 29.1±7.0                     28.6±6.3
  **Eosinophil count**^+^** cells·µL^−1^**                 375 (0--4494)            380 (0--3440)                380 (0--3100)
  **Pre-bronchodilator FEV**~**1**~**^+^** **L**             1.71±0.61                1.70±0.57                    1.70±0.60
  **Pre-bronchodilator FEV**~**1**~**^+^** **% pred**        57.0±14.9                57.9±14.3                    56.5±14.6
  **Pre-bronchodilator FEV**~**1**~**/FVC**^+^** %**           61±13                    61±12                        60±13
  **Reversibility^+^ %**                                   20 (−26--814)            19 (−24--809)                21 (−13--171)
  **Pre-bronchodilator FVC^+^ % pred**                   75.6 (19.2--122.4)       76.3 (21.9--125.3)           76.1 (33.4--143.1)
  **Time since asthma diagnosis years**                   15.5 (1.1--72.4)         15.3 (1.1--70.4)             15.2 (1.1--66.9)
  **Age at asthma diagnosis years**                       31.6 (0.0--72.4)         34.6 (0.0--71.1)             32.0 (0.0--72.0)
  **Exacerbations in the past 12 months n**               2.0 (2.0--20.0)          2.0 (1.0--22.0)              2.0 (1.0--15.0)
  **TASS^+^**                                                 2.7±1.1                  2.7±1.0                      2.7±1.1
  **ACQ-6 score**                                             2.8±0.9                  2.8±0.9                      2.8±0.9
  **AQLQ(S)+12 score^+^**                                     3.9±1.0                  4.0±1.0                      3.9±1.0
  **Nasal polyps**                                            146 (19)                 136 (18)                     135 (18)
  **Atopic**                                                  463 (60)                 444 (59)                     468 (61)
  **OCS use**                                                 109 (14)                 90 (12)                      110 (14)

Data are presented as n, mean±[sd]{.smallcaps}, n (%) or median (range). Q4W: every 4 weeks; Q8W: every 8 weeks (first three doses Q4W); BMI: body mass index; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; TASS: total asthma symptom score; ACQ-6: Asthma Control Questionnaire 6; AQLQ(S)+12: Asthma Quality of Life Questionnaire (standardised) for ≥12 years; OCS: oral corticosteroid. ^\#^: pooled population of n=2295 patients from the SIROCCO and CALIMA studies who received high-dosage inhaled corticosteroid plus long-acting β~2~-agonist; ^¶^: native Hawaiian or other Pacific Islander, American Indian, Alaska Native and Other; ^+^: data not available for all randomised patients.

Clinical factors identified for enhanced efficacy {#s3b}
-------------------------------------------------

Based on the results of the four separate statistical analyses of the same population, as described in the Methods section and [supplementary appendix E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials), the following clinical factors were selected for further evaluation: OCS use, nasal polyposis, pre-bronchodilator FVC \<65% of predicted, three or more exacerbations in the previous year and age at diagnosis ≥18 years. Only the indicated Q8W dosage of benralizumab is discussed in this article. The Q4W results are provided in [supplementary tables E3--E14](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials) for completeness, as they were part of the SIROCCO and CALIMA studies.

Baseline factor influence on benralizumab-mediated exacerbation rate reduction {#s3c}
------------------------------------------------------------------------------

A greater reduction in AER was observed for patients in the overall population and those with blood eosinophil counts ≥300 cells·μL^−1^ receiving benralizumab Q8W and with any baseline factor evaluated compared with the efficacy in the full analysis set (FAS) ([figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, and [supplementary tables E3 and E4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)). For the overall population, OCS use (rate ratio 0.42, 95% CI 0.29--0.60; nominal p\<0.001) and nasal polyposis (rate ratio 0.50, 95% CI 0.35--0.72; nominal p\<0.001) had the greatest influence on improvement of AER with benralizumab Q8W *versus* placebo compared with the FAS, with a rate ratio for the FAS of 0.64 (95% CI 0.55--0.75; nominal p\<0.001). For patients with blood eosinophil counts \<300 cells·μL^−1^, OCS use (rate ratio 0.44, 95% CI 0.26--0.74; nominal p=0.002), nasal polyposis (rate ratio 0.49, 95% CI 0.21--1.19; nominal p=0.115) and pre-bronchodilator FVC \<65% of predicted (rate ratio 0.57, 95% CI 0.36--0.92; nominal p=0.021) had a notable influence on improving benralizumab Q8W AER efficacy compared with the efficacy in the FAS (rate ratio 0.73, 95% CI 0.57--0.94; nominal p=0.013), despite the smaller number of patients ([figure 2](#F2){ref-type="fig"} and [supplementary table E5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).

![Forest plot of baseline factor effect on annual exacerbation rate ratio with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid (ICS) plus long-acting β~2~-agonist (LABA) for the overall population (full analysis set (FAS), pooled). OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity. Data are from the pooled intention-to-treat population from the high-dosage ICS/LABA treatment cohorts of the SIROCCO and CALIMA studies. Estimates were reweighted to account for the 2:1 stratification for baseline blood eosinophil counts (≥300 and \<300 cells·μL^−1^). Estimates were calculated by using a negative binomial model with adjustment for study code, region, OCS use at time of randomisation where applicable, prior year exacerbations and treatment. The log of each patient\'s corresponding follow-up time was used as an offset variable in the model to adjust for different exposure times during which the events occurred.](ERJ-00936-2018.01){#F1}

![Influence of baseline factors on annual exacerbation rate reduction with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid plus long-acting β~2~-agonist (full analysis set (FAS), pooled): a) overall, b) ≥300 eosinophils·μL^−1^ and c) \<300 eosinophils·μL^−1^. OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity. ^\#^: nominal p-value \<0.001; ^¶^: nominal p-value ≥0.001-- ≤0.01; ^+^: nominal p-value \>0.01-- ≤0.05. n-values for number of benralizumab Q8W patients included in the model presented (placebo cohort n-values in [supplementary tables E1--E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).](ERJ-00936-2018.02){#F2}

Baseline factor influence on benralizumab-mediated lung function improvements {#s3d}
-----------------------------------------------------------------------------

Patients with any baseline clinical factor evaluated had greater lung function improvements with benralizumab Q8W *versus* placebo compared with the efficacy in the overall FAS and in the population of patients with blood eosinophil counts ≥300 cells·μL^−1^ ([figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}, and [supplemental tables E6 and E7](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)). For the overall population, nasal polyposis (least squares mean difference 0.29 L, 95% CI 0.17--0.41 L; nominal p\<0.001) and pre-bronchodilator FVC \<65% of predicted (least squares mean difference 0.21 L, 95% CI 0.10--0.31 L; nominal p\<0.001) had the greatest influence on increasing FEV~1~ with benralizumab Q8W *versus* placebo compared with the FAS (least squares mean difference 0.10 L, 95% CI 0.05--0.14 L; nominal p\<0.001). Similarly, for patients with blood eosinophil counts \<300 cells·μL^−1^, nasal polyposis (least squares mean difference 0.24 L, 95% CI 0.0--0.48 L; nominal p=0.045) and pre-bronchodilator FVC \<65% of predicted (least squares mean difference 0.11 L, 95% CI −0.04--0.26 L; nominal p=0.146) had the greatest influence of all evaluated baseline factors on improving benralizumab Q8W FEV~1~ efficacy compared with the efficacy in the FAS (least squares mean difference 0.05 L, 95% CI −0.03--0.12 L; nominal p=0.238) ([figure 4](#F4){ref-type="fig"} and [supplementary table E8](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).

![Forest plot of baseline factor effect on pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV~1~) (L) change (end-of-treatment (EOT)−baseline) improvements with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid (ICS) plus long-acting β~2~-agonist (LABA) for the overall population (full analysis set (FAS), pooled). OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity. Data are from the pooled intention-to-treat population from the high-dosage ICS/LABA treatment cohorts of the SIROCCO and CALIMA studies. Estimates were reweighted to account for the 2:1 stratification for baseline blood eosinophil counts (≥300 and \<300 cells·μL^−1^). Pre-BD FEV~1~ change is from baseline (*i.e.* last value before randomisation) to EOT (SIROCCO: week 48; CALIMA: week 56). Estimates were calculated by using a mixed-effects model for repeated measures analysis with adjustment for study code, treatment, baseline value, region, OCS use at time of randomisation where applicable, visit and visit×treatment.](ERJ-00936-2018.03){#F3}

![Influence of baseline factors on pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV~1~) (L) change (end-of-treatment (EOT)−baseline) improvements with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid plus long-acting β~2~-agonist (full analysis set (FAS), pooled): a) overall, b) ≥300 eosinophils·μL^−1^ and c) \<300 eosinophils·μL^−1^. LS: least squares; OCS: oral corticosteroid; FVC: forced vital capacity. ^\#^: nominal p-value \<0.001; ^¶^: nominal p-value ≥0.001-- ≤0.01; ^+^: nominal p-value \>0.01-- ≤0.05. n-values for number of benralizumab Q8W patients included in the model presented (placebo cohort n-values in [supplementary tables E4--E6](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).](ERJ-00936-2018.04){#F4}

Baseline factor influence on benralizumab-mediated improvements in asthma symptoms and control {#s3e}
----------------------------------------------------------------------------------------------

Greater improvement in asthma symptoms with benralizumab Q8W *versus* placebo was observed for patients, both overall and those with blood eosinophil counts ≥300 cells·μL^−1^, having any baseline factor evaluated (for OCS use, overall only) compared with the efficacy in the FAS ([figure 5](#F5){ref-type="fig"}, and [supplementary tables E9 and E10](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)). The greatest baseline factor-associated reduction in total asthma symptom score for the overall patient population treated with benralizumab Q8W *versus* placebo compared with the efficacy in the FAS (least squares mean difference −0.18, 95% CI −0.30-- −0.07; nominal p=0.002) occurred for those with nasal polyposis (least squares mean difference −0.35, 95% CI −0.59-- −0.10; nominal p=0.005) and OCS use (least squares mean difference −0.31, 95% CI −0.60-- −0.02; nominal p=0.038). For patients with blood eosinophil counts \<300 cells·μL^−1^, nasal polyposis (least squares mean difference −0.46, 95% CI −1.02--0.10; nominal p=0.107) and OCS use (least squares mean difference −0.31, 95% CI −0.80--0.18; nominal p=0.210) had the greatest influence of all evaluated baseline factors on improving benralizumab Q8W total asthma symptom score efficacy compared with the efficacy in the FAS (least squares mean difference −0.14, 95% CI −0.34--0.06; nominal p=0.178) ([figure 5](#F5){ref-type="fig"} and [supplementary table E11](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).

![Influence of baseline factors on total asthma symptom score (TASS) change (end-of-treatment (EOT)−baseline) improvements with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid plus long-acting β~2~-agonist (full analysis set (FAS), pooled): a) overall, b) ≥300 eosinophils·μL^−1^ and c) \<300 eosinophils·μL^−1^. LS: least squares; OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity. ^\#^: nominal p-value \<0.001; ^¶^: nominal p-value ≥0.001-- ≤0.01; ^+^: nominal p-value \>0.01-- ≤0.05. n-values for number of benralizumab Q8W patients included in the model presented (placebo cohort n-values in [supplementary tables E7--E9](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).](ERJ-00936-2018.05){#F5}

For ACQ-6 score, OCS use was consistently the strongest baseline factor associated with enhanced benralizumab Q8W-mediated efficacy improvements relative to placebo, regardless of blood eosinophil count ([figure 6](#F6){ref-type="fig"} and [supplementary tables E12--E14](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)). For patients with blood eosinophil counts \<300 cells·μL^−1^ using OCS, there was a −0.47 least squares mean difference *versus* placebo in ACQ-6 score (95% CI −0.99--0.04; nominal p=0.072) compared with −0.18 least squares mean difference (95% CI −0.37--0.01; nominal p=0.066) for the FAS.

![Influence of baseline factors on Asthma Control Questionnaire 6 (ACQ-6) change (end-of-treatment (EOT)−baseline) improvements with benralizumab every 8 weeks (Q8W, first three doses every 4 weeks) and high-dosage inhaled corticosteroid plus long-acting β~2~-agonist (full analysis set (FAS), pooled): a) overall, b) ≥300 eosinophils·μL^−1^ and c) \<300 eosinophils·μL^−1^. LS: least squares; OCS: oral corticosteroid; BD: bronchodilator; FVC: forced vital capacity; ND: not determined because of small sample size. ^\#^: nominal p-value \<0.001; ^¶^: nominal p-value ≥0.001-- ≤0.01; ^+^: nominal p-value \>0.01-- ≤0.05. n-values for number of benralizumab Q8W patients included in the model presented (placebo cohort n-values in [supplementary tables E10--E12](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)).](ERJ-00936-2018.06){#F6}

Discussion {#s4}
==========

Benralizumab is an anti-eosinophilic monoclonal antibody that depletes eosinophils through antibody-dependent cellular cytotoxicity, and significantly reduces asthma exacerbations and improves disease control for patients with severe, uncontrolled asthma and elevated blood eosinophils \[[@C11], [@C12], [@C26]\]. For patients in the pooled SIROCCO and CALIMA studies receiving high-dosage ICS/LABA and with blood eosinophil counts ≥300 cells·µL^−1^, benralizumab Q8W decreased exacerbations by 42% (p\<0.001) and increased pre-bronchodilator FEV~1~ by 0.14 L (p\<0.001) relative to placebo. In a previous report of the pooled studies, clinical efficacy of benralizumab was associated with elevated baseline blood eosinophil counts and history of exacerbations \[[@C26]\]. Although other predictive clinical features associated with the severe eosinophilic asthma phenotype were reported, these earlier analyses of clinical features were not quantitative and were not specifically evaluated for patients with nonelevated blood eosinophil counts (*i.e.* \<300 cells·μL^−1^), a common clinical presentation \[[@C26]\].

In the current study, we evaluated several baseline clinical factors reported to be associated with the severe eosinophilic asthma phenotype in relation to benralizumab efficacy \[[@C28], [@C29]\]. The selection of these factors was based on several analyses, including the aforementioned unbiased analysis, that evaluated the relative influence of baseline factors on predicting enhanced benralizumab efficacy for reducing exacerbations and improving lung function ([supplementary appendix E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00936-2018.figures-only#fig-data-supplementary-materials)) \[[@C26]\]. These factors included maintenance OCS use, history of nasal polyposis, low lung function based on a pre-bronchodilator FVC \<65% of predicted, adult onset of disease (age ≥18 years) and history of frequent exacerbations (three or more in the previous 12 months).

In this study, OCS use, nasal polyposis, pre-bronchodilator FVC \<65% of predicted, three or more exacerbations in the previous year and age at diagnosis ≥18 years were all associated with enhanced responsiveness to benralizumab Q8W treatment for reducing exacerbations and increasing lung function for the overall patient population and for those with baseline blood eosinophil counts ≥300 cells·μL^−1^. Conversely, patients with none of these features were least responsive to benralizumab Q8W. Although it would be interesting to speculate that patients with a combination of these features would have greater responsiveness to benralizumab than those with individual features, because of low patient numbers, we cannot adequately address this possibility. A total of 12 patients with combined OCS use, nasal polyposis, pre-bronchodilator FVC \<65% of predicted and age at diagnosis ≥18 years treated with benralizumab Q8W demonstrated a 69% (95% CI 25--87%) improvement in exacerbation rates compared with placebo. Patients with a combination of pre-bronchodilator FVC \<65% of predicted, age at diagnosis ≥18 years, OCS use and no nasal polyposis had a 76% (95% CI 45--89%; n=23) improvement, and those with a combination of pre-bronchodilator FVC \<65% of predicted, age at diagnosis ≥18 years, nasal polyposis and no OCS use had a 78% (95% CI 43--91%; n=26) improvement in exacerbation rate with benralizumab Q8W compared with placebo.

Adequate phenotyping of patients with low blood eosinophil counts is particularly important before initiation of a highly targeted asthma biological, such as benralizumab, to help ensure the desired clinical outcome. For example, early trials of anti-IL-5 therapy for largely unselected patients with asthma failed to demonstrate clinical benefit \[[@C30]--[@C32]\]. In the absence of robust baseline response predictors, the success or failure of omalizumab treatment is still mainly based on re-evaluation after a therapeutic trial \[[@C33]\].

For patients with baseline blood eosinophil counts \<300 cells·μL^−1^, OCS use, nasal polyposis and pre-bronchodilator FVC \<65% of predicted had the greatest influence on predicting enhanced response to benralizumab Q8W for decreasing exacerbation rate, whereas history of nasal polyposis and, to a lesser extent, low baseline lung function were the most important factors for influencing benralizumab Q8W responsiveness for improving lung function. It is notable that for the subgroup of patients with blood eosinophil counts \<300 cells·μL^−1^, baseline OCS use, nasal polyps and low lung function continue to be prominent predictors of improvement in asthma exacerbations, and nasal polyps continue to predict FEV~1~ response. We conclude that the presence of these features in patients with severe, exacerbation-prone asthma and blood eosinophil counts \<300 cells·μL^−1^ increases the probability that the patients' asthma is eosinophil mediated. Symptomatic improvements (either total asthma symptom score or ACQ-6) in patients with blood eosinophil counts \<300 cells·μL^−1^ were most consistently associated with current OCS use.

Several of these identified characteristics are associated with the potential pathogenic effects of eosinophilic airway inflammation. Greater airway eosinophil counts are associated with poor lung function \[[@C34]\], airway remodelling \[[@C35]\] and gas trapping \[[@C28]\], which reflect the characteristic of low lung function to predict enhanced benralizumab response. Elevated blood eosinophil counts are also associated with high exacerbation frequency \[[@C9]\], supporting the observation of exacerbation history as a predictor of response. Nasal polyposis was the most consistent predictor of benralizumab response, regardless of baseline blood eosinophil count. This is consistent with the fact that nasal polyposis is highly associated with eosinophilic inflammation of the upper airway \[[@C36]\], which tends to correlate with inflammation of the lower airway \[[@C37]\]. Hence, several of these baseline clinical features are related to the pathology of eosinophilic inflammation.

These results also indicate a potential benefit of benralizumab for patients with baseline factors that are associated with severe eosinophilic asthma, such as those evaluated in this study. For example, long-term OCS treatment is an option for patients with asthma not controlled with conventional therapies such as high-dosage ICS/LABA \[[@C4], [@C7]\]. The presence of nasal polyps for patients with adult-onset asthma is predictive of asthma severity \[[@C38]\]. Low FVC is associated with hyperinflation, air trapping and airflow obstruction for patients with severe asthma and with an increased risk of exacerbations \[[@C39], [@C40]\]. Thus, benralizumab treatment for patients with these baseline clinical features may modulate associated consequences of these clinical features.

One of the limitations of this study was the lower number of patients with blood eosinophil counts \<300 cells·μL^−1^ and some of the respective baseline factors evaluated. Subsequently, only trends could be identified in this subgroup; further analysis with a larger number of patients would be needed to confirm these results. For the entire pooled analyses, all comparator results of benralizumab compared with placebo used nominal p-values as they were not part of the predetermined general testing strategy. Therefore, no formal statistical significance could be inferred. Another limitation of this study was that certain baseline factors were self-reported (*e.g.* nasal polyposis) and so their prevalence may have been underestimated. Despite these limitations, the analyses reported in this article provide an evidence-based approach for targeted therapy with benralizumab.

In conclusion, this article describes several clinical characteristics also associated with the severe eosinophilic asthma phenotype \[[@C28]\] that complement baseline blood eosinophil counts in predicting a treatment response to benralizumab for patients with severe, uncontrolled asthma. They include OCS use, nasal polyposis, low lung function, history of frequent exacerbations and adult onset of disease. These features are easily assessed by healthcare professionals in an office setting and should help inform clinical decisions on the use of benralizumab for specific patients.

Supplementary material {#s5}
======================

10.1183/13993003.00936-2018.Supp1

**Please note:** supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material ERJ-00936-2018_Supplement

Writing and editing support, including preparation of the draft manuscript under the direction and guidance of the authors, incorporating author feedback and manuscript submission, was provided by Alan Saltzman of JK Associates (Conshohocken, PA, USA) and Michael A. Nissen of AstraZeneca (Gaithersburg, MD, USA).

This article has supplementary material available from [erj.ersjournals.com](erj.ersjournals.com)

Conflict of interest: E.R. Bleecker has performed clinical trials through his former employer, the Wake Forest School of Medicine, and his current employer, the University of Arizona; and has served as a paid consultant for AstraZeneca/MedImmune, Boehringer Ingelheim, GSK, Novartis, Regeneron and Sanofi-Genzyme.

Conflict of interest: M.E. Wechsler received consulting honoraria from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Regeneron, Sanofi and Teva.

Conflict of interest: J.M. FitzGerald is an advisory board member for ALK, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Sanofi-Regeneron and Teva, and has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Cephalon/Teva, Forest, Genentech, GSK, Johnson and Johnson (Janssen), MedImmune, Novartis, Pfizer and Sanofi.

Conflict of interest: A. Menzies-Gow has consultancy agreements with AstraZeneca and Vectura, was an advisory board member for AstraZeneca, Boehringer Ingelheim, GSK, Novartis and Teva, received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Teva, and Vectura; has participated in research that his institution has been renumerated from Boehringer Ingelheim, GSK and Hoffman La Roche, and has attended international conferences sponsored by AstraZeneca and Boehringer Ingelheim.

Conflict of interest: Y. Wu is an employee of AstraZeneca.

Conflict of interest: I. Hirsch is an employee of AstraZeneca.

Conflict of interest: M. Goldman is an employee of AstraZeneca.

Conflict of interest: P. Newbold is an employee of MedImmune LLC.

Conflict of interest: J.G. Zangrilli is an employee of AstraZeneca.

Support statement: Funding for this study was provided by AstraZeneca. Funding information for this article has been deposited with the [Crossref Funder Registry](https://www.crossref.org/services/funder-registry/).
